Screener
NeoGenomics NEO EPS (Diluted)
Discontinued — last reported Q2 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income tax benefit | 412 | 724 | 884 | 458 |
| NET INCOME (LOSS) | $2,238 | $(45,092) | $(14,868) | $(71,015) |
| NET INCOME (LOSS) PER SHARE | ||||
| Basic | $0.02 | $(0.35) | $(0.11) | $(0.56) |
| Diluted | $0.02 | $(0.35) | $(0.11) | $(0.56) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||||
| Basic | 129,628 | 127,949 | 129,398 | 127,664 |
| Diluted | 130,831 | 127,949 | 129,398 | 127,664 |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's EPS (diluted)?
- NeoGenomics (NEO) reported EPS (diluted) of $0.02 in Q2 2026.
- How has NeoGenomics's EPS (diluted) changed year-over-year?
- NeoGenomics's EPS (diluted) increased by 105.7% year-over-year, from -$0.35 to $0.02.
- What is the long-term trend for NeoGenomics's EPS (diluted)?
- Over 4 years (2021 to 2025), NeoGenomics's EPS (diluted) has grown at a 62.2% compound annual growth rate (CAGR), from -$0.12 to -$0.83.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about NeoGenomics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude